Analytical Data
-
Gene name
BCL2L14
- Application
-
Alternative Names
Apoptosis regulator Bcl-G
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BZR8
-
Expression Region
1-327aa
-
Molecular Weight
63.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BCL2L14, also known as BH3-only protein, is a member of the BCL-2 protein family, which plays a critical role in the regulation of apoptosis and cell survival. The BCL-2 family proteins are crucial in the intrinsic pathway of apoptosis, with BH3-only proteins acting as pro-apoptotic factors that initiate cell death in response to various stressors. The emerging role of BCL2L14 in cancer biology has garnered attention, as its expression levels have been correlated with tumor progression and response to therapy in various cancers. Previous studies suggest that BCL2L14 may function as a tumor suppressor by enhancing apoptosis in response to oncogenic signals, thereby inhibiting tumor cell proliferation. Additionally, the modulation of BCL2L14 activity has been linked to resistance to chemotherapy, making it a potential therapeutic target for enhancing the efficacy of cancer treatments. Understanding the functional mechanisms of BCL2L14 at the molecular level, including its interactions with other BCL-2 family members and associated signaling pathways, is critical for developing novel therapeutic strategies aimed at manipulating cell survival in cancer and other diseases. Hence, research on recombinant BCL2L14 protein not only provides insights into its biological functions but also paves the way for potential interventions that could leverage its pro-apoptotic properties in clinical applications, offering hope for improving patient outcomes in oncology.
